多发性骨髓瘤患者两剂 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体反应。
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
机构信息
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
BACKGROUND
Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.
RESULTS
Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.
CONCLUSIONS
Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.
背景
多发性骨髓瘤（MM）患者被排除在最初的 SARS-CoV-2 mRNA 疫苗试验之外，这可能会影响该人群对疫苗的犹豫。我们前瞻性地描述了 44 名 MM 患者接受两剂 SARS-CoV-2 mRNA 疫苗接种的安全性和免疫原性，这些患者于 2020 年 12 月 17 日至 2021 年 3 月 18 日接受了疫苗接种。
结果
不良反应发生率低，与疫苗试验中记录的一致。在接受 MM 治疗的患者中，93%的患者在接受第 2 剂后可检测到抗受体结合域（RBD）抗体，而 94%未接受 MM 治疗的患者出现血清转化。
结论
两剂 SARS-CoV-2 mRNA 疫苗接种具有轻度的反应原性，可导致 MM 患者血清转化率高。这些发现可以为对接受 SARS-CoV-2 mRNA 疫苗犹豫不决的 MM 患者提供信心。
Zotero 插件